Investor Presentation H1 2023

92 Investor presentation First six months of 2023 Novo NordiskⓇ While Norditropin® is the market leader within GHD market, SogroyaⓇ represents an opportunity for patients Novo Nordisk leadership in competitive hGH market Value MS% 36% 37% 36% 33% 30% SOGROYAⓇ somapacitan 18% 16% 14% 14% 14% 12% 13% 14% 15% 16% • A portfolio offering across markets SogroyaⓇ strategy • Once-weekly efficacious treatment on par with NorditropinⓇ Simple and easy-to-use device Phase 3 trials toward broad range of indications (e.g. SGA, Turner, Noonan, ISS) to expand the market Approved for GHD in US, EU and Japan 38% 36% 36% 37% 37% H1 2021 H2 2021 H1 2022 H2 2022 H1 2023 Novo Nordisk Company A Company B Others norditropinⓇ (somatropin) injection hGH: Human growth hormone; SGA: Small for gestational age, ISS; Idiopathic short stature Source: IQVIA, MAT May 2023. Due to contractual obligations competitor names are not disclosed. Company A and B represent actual companies NorditropinⓇ strategy Apply a market-fit approach to support specific markets and patient groups Broad label across eight indications

View entire presentation